CLINICAL_TRIALS
trial_result
· 2023-12-28
Clinical Trial Update: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss [Phase 3]
Summary
A Phase 3 clinical trial of solanezumab in older individuals at risk for memory loss has completed; results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Cognition Disorders | Phase 3 | Status: COMPLETED | Results posted: 2023-12-28